HONG KONG – CAR T biotech Immunochina Pharmaceuticals Co. Ltd. raised ¥140 million (US$20.7 million) in a series C funding round to further develop its lead CAR T therapy targeting CD19, known as IM-19, to compete with Novartis AG's Kymriah (tisagenlecleucel).